Clinerion’s Patient Network Explorer Offers Trial Performance Data
Clinerion’s Patient Network Explorer adds new, actionable functionality to support clinical trial sponsors during site selection as a result of Clinerion’s collaboration with LongTaal, a clinical trial informatics company. The platform now shows current and historical clinical trial performance data for all partner hospitals and trial sites in Clinerion’s worldwide patient network.
Effective immediately, users of Clinerion’s Patient Network Explorer can review detailed clinical trial statistics on an individual hospital level. Derived and mapped from multiple public sources, this new functionality allows for browsing, filtering, reviewing, and comparing site trial performance statistics, including breakdowns on studies by sponsor, by condition, by trial phase and by recruitment status.
The possibility to further filter by study status, sponsor, phase, or condition offers detailed results and a list of the respective studies which provides more information such as on other locations where the study is being conducted.
“It is crucial, during site selection, to have as much information at hand as possible, to avoid expensive detours and dead ends,” says Ian Rentsch, CEO of Clinerion. “Patient Network Explorer is becoming everything a sponsor needs to identify the right site for their trials.”
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
